Syenza’s News Roundup: Launching a New Era of Healthcare Insights

By Staff Writer

September 7, 2023

We are excited to announce the launch of our new newsletter, “Value Science Weekly”. This weekly digest is designed to keep you up-to-date on the latest trends, insights, and breakthroughs in Health Economics and Outcomes Research (HEOR), Global Market Access, and Dynamic Intelligence.

In our next week’s issue, we delve into the transformative potential of virtual care in neurology, as highlighted by the World Health Organization. The rising demand for continuous home and institutional care, driven by an ageing population and increasing prevalence of chronic diseases, is being met head-on by advancements in virtual care. Our rapid insight article explores how virtual care is reshaping patient evaluation, treatment, and follow-up, particularly in the field of neurology.

But that’s just the beginning. Each week, our newsletter will bring you expert perspectives and thought-provoking analyses from renowned researchers and industry leaders. You’ll also discover the latest studies and real-world evidence shaping the economic value and patient outcomes of healthcare interventions. Plus, we’ll keep you informed about policy changes, regulatory updates, and reimbursement frameworks that could impact your work.

We’re also excited to share innovations in market access and healthcare delivery, showcasing the cutting-edge technologies and transformative approaches that are emerging in our industry.

Don’t miss out on these valuable insights. Subscribe to “Value Science Weekly” today for your weekly dose of healthcare innovation news. We look forward to embarking on this journey with you.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.